Current status and prospects in treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults

VernacularTitle:成年人费城染色体阳性急性淋巴细胞白血病治疗现状及展望
Author: Meifang ZHAO ¹ ; Yehui TAN
Author Information

1. 吉林大学第一医院血液科，长春　130000
From: Journal of Leukemia & Lymphoma 2020;29(8):509-512
CountryChina
Language:Chinese
Abstract: The effect of traditional chemotherapy on Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) in adults is not satisfactory. With the introduction of tyrosine kinase inhibitor (TKI), the treatment paradigms and overall survival of adult patients with Ph + ALL have been improved. In the era of TKI, there is no consensus so far on the following issues, whether transplantation is still necessary, how to apply TKI before and after transplantation, what are the new advances in immunotherapy, and the effect of immunotherapy combined with targeted therapy. This article reviews the current treatment status and prospects in Ph + ALL.